9 / 13
Allied Journal of Medical Research
|
Volume 2
Page 49
allied
academies
CANCER THERAPY AND ONCOLOGY
NEUROLOGY AND BRAIN DISORDERS
&
International Conference on
International Conference on
J u n e 2 1 - 2 2 , 2 0 1 8 | O s a k a , J a p a n
Joint Event on
PERSONALIZED AND PRECISION ONCOLOGY THROUGH THE
VIEW OF TRANSLATIONAL APPLICATIONS AND INNOVATIVE
TOOLS TO MANAGE CANCER PROGRESSION
Sergey Suchkov
1,7
, Vladimir Lazar
8
and
John Mendelsohn
8,9
1
Sechenov University, Russia
2
Moscow Engineering Physical Institute (MEPhI, Russia
3
A.I.Evdokimov Moscow State Medical & Dental University, Russia
4
ISPM, Tokyo, Japan
5
PMC, Washington, USA
6
EPMA, Belgium
7
AHA, Houston, USA
8
WIN Consortium, France
9
University of Texas MD Anderson Cancer Center, USA
A
new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely,
personalized and precision medicine (PPM) to stimulate the development in a variety of clinical disciplines including
Personalized and Precision Oncology (PPO). To achieve the implementation of PPO concept into the daily practice, it is
necessary to create a fundamentally newstrategy based upon the subclinical recognition of cancer-associated bioindicators
(biopredictors andbiomarkers) of pre-cancer abnormalities longbefore thedisease clinicallymanifests itself. Eachdecision-
maker values the impact of their decision to use PPO on their own budget and well-being, which may not necessarily be
optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for
applications such as prediction and personalization of further treatment to thus provide more tailored measures for the
cancer patients and persons-at-risk resulting in improved outcomes whilst securing the healthy state and wellness, reduced
adverse events, and more cost effective use of health care resources. Rapidly improving understanding of PPO, emerging
novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for
delivering genomically informed personalized cancer therapy. Alterations that are targetable either directly or indirectly
with approved or investigational therapies are potentially “actionable”. At this time, evidence linking predictive biomarkers
to therapies is strong for only a few genomic markers in the context of specific cancer types. Deciding what therapy options
to pursue can also be daunting, especially when tumors harbor more than one potentially actionable aberration. Further,
different mutations/variants in a single gene may have different functional consequences, and response to targeted
agents may be context dependent. However, early clinical trials with new molecular entities are increasingly conducted in
a biomarker-selected fashion, and even when trials are not biomarker-selected, much effort is placed on enrolling patients
onto clinical trials where they have the highest probability of response. Implementation of PPO requires a lot before the
current model “oncologist-cancer patient” could be gradually displaced by a new model “medical advisor-healthy person-
at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPO to
elicit the content of the new branch. Recognizing the need to define the policies required for sustained innovation in cancer
research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and
identify areas for collaboration.
ssuchkov57@gmail.comAllied J Med Res 2018, Volume 2